Axa’s Unity Biotechnology UBX Stock Holding History

Axa’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,100	Closed	-$97K	–	1327
2021 Q2	$97K	Sell	2,100 -9,720	-82%	-$468K	﹤0.01%	1240
2021 Q1	$709K	Buy	+11,820	New	+$806K	﹤0.01%	1033

Other funds holding UBX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FFVM

Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Axa's UBX Position: Q3 2021 in Review

Axa sold out of Unity Biotechnology (UBX) in Q3 2021, closing a stake of 2,100 shares — an estimated $97K sold.

Axa first reported a position in UBX in Q1 2021 and held it in 2 quarters. The position peaked at $709K in Q1 2021. 84 funds tracked by Wall St. Rank hold UBX as of Q3 2021.

Axa reported no remaining Unity Biotechnology position as of Q3 2021 after selling out during the quarter.
Axa sold 2,100 Unity Biotechnology shares in Q3 2021, an estimated $97K.
Axa first reported a position in Unity Biotechnology in Q1 2021 and held it in 2 quarters.
Axa's Unity Biotechnology position peaked at $709K in Q1 2021.
84 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2021.

Based on Axa's 13F filing for Q3 2021, filed 15 Nov 2021.